Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up
Outlook Therapeutics soared 26% to $0.89 on heavy volume as investors zeroed in on the FDA’s 60-day review window for Lytenava after a successful appeal, but risks remain with the stock still under $1, looming Nasdaq compliance deadlines, and warnings of possible dilution and going-concern doubts if FDA approval or favorable labeling isn’t secured soon.